Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
Retrieved on:
Wednesday, November 30, 2022
COVID-19, Doctor of Philosophy, JD, European Medicines Agency, Intellectual disability, MAA, Piper Sandler Companies, Frank Lenti, MS, Osteoporosis, Engineering, Metabolic disorder, Conference, Compte rendu, Multimedia, Therapy, Physician, Enzyme, MBA, Patient, Massachusetts Institute of Technology, Genzyme, Disease, CBS, Cornell University, Marfanoid, Security (finance), Proteostasis, Death, Risk, Arginine, Chemical engineering, Pharmaceutical industry, Management, Homocystinuria
Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics.
Key Points:
- Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics.
- I look forward to working closely with Jeff and welcome him to the Aeglea team."
- Mr. Goldberg served as president and chief executive officer at Immunitas from 2019-2021.
- Jim Kastenmayer, JD, PhD, will step down as interim chief executive officer and retain his position as Aeglea's general counsel.